French Trial Tragedy May Spark Change In EU Phase I Risk Assessments
This article was originally published in SRA
Drug regulators in the EU are looking closely at the way that Phase I studies are planned and designed amid calls for better protection for volunteers in the wake of the French BIA 10-2474 trial tragedy. Among topics likely to be under consideration are a more consistent approach to determining the potential risk of novel compounds, and greater use of sequential dosing in first-in-human clinical trials.
You may also be interested in...
Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts
The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.
Australia will begin its coronavirus vaccination program with Comirnaty. The Oxford University/AstraZeneca vaccine is expected to be the next to receive approval.
Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.